Use of filtered vs. Nonfiltered Residual circuit volume, a comparative study

Authors

Mainak De¹, Kamal Das², Milan Manna³, Manisha Halder⁴, Sujoy Poddar⁵
Sudipta Patra⁶

¹,³,⁴,⁵ 3rd yr B.Sc Perfusion Technology, Dept of CTVS, R.G.Kar Medical College, Kolkata
² M.Sc Perfusion Science, Chief Perfusionist, Dept of CTVS, R.G.Kar Medical College, Kolkata
⁶ 2nd yr M.Sc Perfusion Science, Dept of CTVS, R.G.Kar Medical College, Kolkata, India

Abstract

Cardiac surgery causes large amount of blood loss in form of CPB circuit residual volume. Re infusion of the circuit volume reduces homologous blood requirements and thereby eliminates the adverse effects of homologous blood. But unprocessed residual blood retransfusion itself can have tremendous hazards which may lead to increased post op bleeding, increased homologous blood requirement, SIRS which may ultimately lead to organ dysfunction¹. These unwanted effects of unprocessed residual CPB circuit volume can be eliminated by processing it² as processing by various methods and devices reduce amount of active inflammatory mediators³,⁴. Due to low cost effectiveness of cell salvage technique we used haemofiltration as a technique to decrease load of activated inflammatory factors⁵. Our study includes two groups Group A (n=25) who were transfused with unprocessed residual circuit volume and Group B (n=25) who were transfused with residual blood transfused after processing it through haemofiltration. In Group B we observed lower blood and blood product requirement, less bleeding in 24 hour post operatively and reduced ventilatory stay than Group A.

Keywords: Circuit residual volume, haemofiltration, blood loss, Inflammation, autologous blood transfusion.

Introduction

One of the major complications in cardiac surgery with cardiopulmonary bypass is excessive intraoperative and postoperative blood loss. Blood loss usually is compensated by infusion of homologous blood products which may cause number of adverse reactions like febrile haemolytic and nonhaemolytic transfusion reaction, TRALI, septicemia, endotoxemia etc⁶,⁷. With increasing number of open heart surgery day by day, it is putting tremendous load on blood banks also. For these reasons, it is important to reduce the need for transfusion of allogenic blood.

After any operation with CPB extensive form of blood loss occurs in form of the blood volume which remains in total circuit which is called residual circuit volume. The amount of volume includes circuit’s priming volume and volume gained from cardiotomy suctions after venous decannulation. To minimize loss of blood this residual volume is often given. It is a type of autologous blood transfusion.

Now CPB involves extensive contact between blood and nonphysiologic artificial surface of circuit which cause activation of complement cascade, fibrinolysis, loss of coagulation factors,
induction of systemic inflammatory response. So transfusion of unprocessed residual blood volume of CPB can cause more post operative blood loss and may increase SIRS. In particular the products generated after cleavage of C3 namely C3a & C3b stimulates release of histamine and other inflammatory mediators from mast cell and basophiles. This results in smooth muscle constriction and an increase in vascular permeability. Cleavage of C5 results in production of C5a & C5b. C5a is a potent chemotactic factor for neutrophil and promotes aggregation, adhesion and activation of neutrophils. C3b & C5b interact on cell membrane with components C6-C9 to form membrane attack complex which activates platelets and damages cell membrane. Other mediators for SIRS are cytokines, TNF alfa, interleukins etc.

To decrease the adverse reaction caused by the infusion of unprocessed residual volume, filtration is an alternative method. Filtration and washing reduces load of activated complement factors very significantly which causes less inflammatory response and post operative bleeding.

Processing of residual blood with cell saver machine can also be an alternative but in comparison to salvaged blood which is only washed RBC, filtered blood contains RBCs as well as other components like fresh plasma, platelets etc and is also cost effective.

Material & Methods

50 patients undergoing elective cardiac surgery (e.g ASD, VSD, MVR, AVR, DVR, CABG on pump) were prospectively enrolled in this study. Patient aged less than 18 years were excluded from this study. All the patients were divided into two groups- Group A (n=25) and Group B (n=25). In group A (n=25) after completion of operation non filtered residual circuit volume was transfused and in Group B (n=25) washed and filtered residual volume was transfused.

All surgeries of both groups were performed using a standard general anaesthesia protocol, median sternotomy approach, employing cardiopulmonary bypass with mild to moderate hypothermia (28°C - 35°C) and cardioplegic arrest (antegrade). Topical hypothermia was performed by cold ice saline intermittently.

CPB circuit consisted membrane oxygenator, with heat exchanger, a custom made uncoated PVC tubing pack with siliconized roller pump head tubing, arterial line filter (and haemofilter in group B patients). Circuit was primed with 1200-1400 ml RL/RI, 20ml NaHCO3 8.4%, 5.4IU heparin/ml priming volume.

Before cannulation, the patients were heparinised with 300IU heparin/kg body weight to achieve ACT>480 sec and throughout CPB ACT is maintained above 480 sec.

Throughout CPB mean arterial pressure was maintained 50-60mmHg.

In all patients after CPB heparin was neutralized with protamine sulphate and sternum was closed after thorough checking of haemostat by senior surgeon.

In Group A patients residual volume, after detachment of venous line from patient and collecting the blood volume of venous line in reservoir, was given through arterial line without filtration at slow rate before administration of protamine and circuit volume replaced by Ringer Lactate solution. After that protamine was given.

In Group B patients residual volume after detachment of venous line from patient and collecting the blood volume from venous line into reservoir, first the arterial line was clamped. Then the blood was circulated through haemofilter @ 400-500ml/min maintaining line pressure less than 100mmHg till a certain amount of filtrate (in average 400ml) filtrate was filtered out. The arterial line then was unclamped, filter was clamped and pump flow was reduced to 200ml/min and residual volume was given and replaced by Ringer Lactate solution (Ringers Chase technique). Then protamine was started.
Then the post operative data of both group of patient of ventilator stay, drainage within 24 hours, homologous blood requirement were recorded and were analysed by statistical software “SPSS” version

Result
Out of 50 patients 16 patients (32%) were female and 34(68%) were male. All of them were aged between 25 to 60 years.
In group A (n=25) 21 patients (84%) required total blood and blood products more than 5 units and for 18(72%) patients bleeding were more than 500 ml during the first 24 hour after operation. In Group A patients inotropic requirement was also high as well as ventilator stay was also longer.
In group B (n=25) only 9 patients (36%) required total blood and blood products more than 5 units and only 7 patients (28%) bleed more than 500 ml in first 24 hour after surgery. Inotropic requirement and ventilator stay were also reduced.
No death occurred during this study.

Table 1: Data of group A patients

| Sl no. | Age/Sex | Procedure       | Residual volume transfused(ml) | Blood and Blood Product requirement | Drainage (ml) in 1st 24 hour | Ventilator stay/hr |
|--------|---------|-----------------|-------------------------------|------------------------------------|-----------------------------|-------------------|
| 1      | 35/m    | MVR             | 1000                          | 2PRBC, 3FFP, 3Platelet              | 600                         | 23                |
| 2      | 29/M    | OS-ASD closure  | 1000                          | 1PRBC, 4FFP, 3Platelet              | 570                         | 18                |
| 3      | 31/F    | AVR             | 1200                          | 2PRBC, 3FFP, 3Platelet              | 650                         | 28                |
| 4      | 60/M    | CABG-On pump    | 1000                          | 3PRBC, 3FFP, 2Platelet              | 750                         | 34                |
| 5      | 25/M    | SV ASD with PAPVC| 1100                        | 1PRBC, 2FFP, 1Platelet              | 430                         | 24                |
| 6      | 36/F    | MVR             | 1400                          | 2PRBC, 3FFP, 4Platelet              | 850                         | 41                |
| 7      | 45/M    | AVR             | 1000                          | 1PRBC, 4FFP, 3Platelet              | 575                         | 21                |
| 8      | 31/M    | OS-ASD closure  | 1200                          | 1PRBC, 4FFP, 4Platelet              | 450                         | 17                |
| 9      | 33/M    | MVR             | 1500                          | 3PRBC, 5FFP, 4Platelet              | 790                         | 40                |
| 10     | 26/M    | OS-ASD closure  | 1000                          | 0PRBC, 3FFP, 1Platelet              | 300                         | 12                |
| 11     | 56/M    | CABG-On pump    | 1250                          | 2PRBC, 3FFP, 3Platelet              | 650                         | 26                |
| 12     | 28/M    | OS-ASD closure  | 1000                          | 0PRBC, 4FFP, 3Platelet              | 320                         | 13                |
| 13     | 37/F    | MVR             | 1400                          | 4PRBC, 6FFP, 4Platelet              | 940                         | 53                |
| 14     | 39/F    | MVR             | 1250                          | 1PRBC, 4FFP, 4Platelet              | 400                         | 29                |
| 15     | 59/M    | CABG-On pump    | 1000                          | 3PRBC, 4FFP, 4Platelet              | 780                         | 31                |
| 16     | 36/M    | MVR             | 1000                          | 0PRBC, 2FFP, 2Platelet              | 300                         | 18                |
| 17     | 27/F    | OS-ASD closure  | 1000                          | 1PRBC, 2FFP, 0Platelet              | 290                         | 18                |
| 18     | 43/M    | AVR             | 1250                          | 2PRBC, 3FFP, 4Platelet              | 630                         | 18                |
| 19     | 41/M    | MVR             | 1500                          | 2PRBC, 2FFP, 2Platelet              | 590                         | 27                |
| 20     | 25/M    | OS-ASD closure  | 1000                          | 1PRBC, 3FFP, 3Platelet              | 340                         | 14                |
| 21     | 32/M    | MVR             | 1500                          | 3PRBC, 5FFP, 5Platelet              | 700                         | 38                |
| 22     | 38/M    | DVR             | 1500                          | 4PRBC, 5FFP, 4Platelet              | 880                         | 49                |
| 23     | 29/M    | OS-ASD closure  | 1000                          | 1PRBC, 3FFP, 2Platelet              | 370                         | 18                |
| 24     | 31/M    | MVR             | 1000                          | 2PRBC, 4FFP, 4Platelet              | 790                         | 36                |
| 25     | 43/M    | DVR             | 1250                          | 1PRBC, 5FFP, 3Platelet              | 540                         | 29                |
We also did organ dysfunction evaluation using Sequential Organ Failure Assessment (SOFA) \(^\text{10}\) scoring system.

**Table 3 :** Average SOFA score of group A and group B patients

| Sl. No. | Age/Sex | Procedure       | Residual volume transfused(ml) | Filtered volume(ml) | Blood & Blood Product requirement | Drainage in 24 hr(ml) | ventilator stay(hr) |
|---------|---------|-----------------|--------------------------------|---------------------|-----------------------------------|----------------------|--------------------|
| 1       | 26/F    | AVR             | 1000                           | 400                 | 0PRBC, 3FFP, 3PLATELET            | 300                  | 20                 |
| 2       | 46/M    | CABG on pump    | 1100                           | 400                 | 0PRBC, 4FFP, 0PLATELET            | 250                  | 20                 |
| 3       | 36/F    | CABG on pump    | 1150                           | 550                 | 1PRBC, 3FFP, 0PLATELET            | 250                  | 20                 |
| 4       | 44/F    | DVR             | 1000                           | 450                 | 1PRBC, 3FFP, 3PLATELET            | 350                  | 18                 |
| 5       | 48/F    | MVR             | 1000                           | 380                 | NIL                               | NIL                  | 17                 |
| 6       | 60/M    | CABG on pump    | 1350                           | 400                 | 2PRBC, 4FFP, 2PLATELET            | 800                  | 48                 |
| 7       | 45/M    | CABG on pump    | 1500                           | 550                 | 1PRBC, 3FFP, 3PLATELET            | 200                  | 18                 |
| 8       | 28/F    | OS-ASD closure  | 1100                           | 400                 | 0PRBC, 2FFP, 0PLATELET            | 50                   | 15                 |
| 9       | 40/F    | OS-ASD closure  | 1000                           | 350                 | 0PRBC, 3FFP, 3PLATELET            | 675                  | 34                 |
| 10      | 54/F    | AVR             | 1000                           | 300                 | 0PRBC, 3FFP, 3PLATELET            | 175                  | 20                 |
| 11      | 39/F    | OS-ASD closure  | 900                            | 200                 | 0PRBC, 2FFP, 1PLATELET            | 400                  | 20                 |
| 12      | 56/M    | CABG on pump    | 1000                           | 350                 | 1PRBC, 3FFP, 3PLATELET            | 1000                 | 49                 |
| 13      | 32/M    | AVR             | 1200                           | 450                 | 3PRBC, 3FFP, 4PLATELET            | 200                  | 24                 |
| 14      | 26/M    | OS-ASD closure  | 950                            | 350                 | 0PRBC, 3FFP, 3PLATELET            | 250                  | 20                 |
| 15      | 43/M    | MVR             | 1250                           | 400                 | 0PRBC, 3FFP, 1PLATELET            | 250                  | 20                 |
| 16      | 25/M    | OS-ASD closure  | 1000                           | 200                 | 0PRBC, 3FFP, 2PLATELET            | 250                  | 20                 |
| 17      | 35/M    | MVR             | 1250                           | 400                 | 1PRBC, 3FFP, 0PLATELET            | NIL                  | 20                 |
| 18      | 39/M    | DVR             | 1500                           | 450                 | 2PRBC, 3FFP, 3PLATELET            | 325                  | 24                 |
| 19      | 28/F    | OS-ASD closure  | 1000                           | 250                 | 0PRBC, 2FFP, 0PLATELET            | NIL                  | 17                 |
| 20      | 56/M    | CABG on pump    | 1200                           | 375                 | 0PRBC, 3FFP, 2PLATELET            | 50                   | 20                 |
| 21      | 33/F    | OS-ASD closure  | 900                            | 250                 | NIL                               | 125                  | 19                 |
| 22      | 37/M    | DVR             | 1000                           | 250                 | NIL                               | 75                   | 20                 |
| 23      | 26/M    | OS-ASD closure  | 650                            | 300                 | 0PRBC, 2FFP, 0PLATELET            | 250                  | 20                 |
| 24      | 30/M    | MVR             | 1000                           | 350                 | 3PRBC, 5FFP, 4PLATELET            | 850                  | 34                 |
| 25      | 51/M    | DVR             | 970                            | 200                 | 1PRBC, 3FFP, 0PLATELET            | 575                  | 20                 |

**Discussion**

Cardiopulmonary bypass offers various challenging situation one of which is decreasing the need for homologous blood after cardiac surgeries. The most extensive form of blood loss during cardiac surgery occurs in form of CPB circuit residual volume. A common technique of autologous transfusion is reinfusion of circuit’s residual volume.

Now, several studies show that unprocessed residual blood has many deleterious effects such as increased post op bleeding, development of SIRS.

In our study we also observed these deleterious effects in group A patients in whom unprocessed residual blood was transfused. There was increased bleeding and increased requirement of autologous blood.

So, we sought an alternative to process the residual blood volume through haemofilter before transfusion.

In group B we first filtered the residual blood and then transfused it to the patient and got satisfactory result. There was decreased bleeding. Many other studies also suggest that haemofiltration reduces the inflammatory mediator \(^\text{11}\). In our study this fact can be partially proved by reduced ventilator stay as observed in patients of Group B than Group A patients. And also in Group B patients SOFA score after 24 hours of surgery were also relatively lower than Group A patients.

**Result Analysis**

Significant decrease in blood and blood product requirements in group B (n=25) patients than in group A (n=25) patients. Average blood and blood product requirement in group A patients is 8.5 unit
while in group B patients average requirement is 4.76 unit. P value = 0.008 i.e, significant.
Drainage within ist 24 hour was also less in group B(average296 ml) where as in group A average was 579.4 ml. P value is =0.001 i.e significant.

In group B average ventilator stay(average 22.8 hour) was also low than group A (average27.4 hour) as well as average SOFA score measured after 24 hour of surgery.

**Conclusion**
After cardiac surgery in CPB, transfusion of the filtered circuit residual volume is useful in an attempt to reduce post operative autologous blood requirement along with reduction in post operative bleeding and also inflammatory reaction due to transfusion of unfiltered residual volume may be avoided. No morbidity and mortality occurred due to this procedure. So to decrease post operative homologous blood product transfusion this technique can be successfully performed with good outcome.

**Financial support & sponsorship:** Nil

**Conflicts of interest:** Not declared
References
1. Yolande-Leigh Iyes et al. The effects on coagulation of the reinfusion of unprocessed residual blood from the cardiopulmonary bypass. BMC Res Notes (2016) 9:61
2. Danne CR, et al. Processing and transfusion of residual cardiopulmonary bypass volume: effects on haemstasis, complement activation, postoperative blood loss and transfusion volume. Perfusion. 2003 Apr; 18(2): 115-21
3. Amand T et al. Levels of inflammatory markers in the blood processed by autotransfusion devices during cardiac surgery associated with cardiopulmonary bypass circuit. Perfusion 2002; 17: 117-23
4. Walpoth BH et al. Effects of unprocessed and processed cardiopulmonary bypass blood retransfused into patients after cardiac surgery. Int J Artif Organs 1999; 22: 210-16
5. Richard D Tallman et al. Inflammatory mediator removal by zero-balance ultrafiltration during cardiopulmonary bypass. Perfusion 2002;17: 111-115
6. Carlos Marcucci et al. Allogenic blood transfusion: benefit, risks and clinical indicators in countries with a low or high human development index British Medical Bulletin, Volume 70, Issue 1, 1 January
7. Dalrymple-Hay MJ, Dawkins S, Pack L et al. Autotransfusion decreases blood usage following cardiac surgery a prospective randomized trial. CardiovascSurg 2001; 9: 184/87
8. Li S et al. Systemic inflammatory response during cardiopulmonary bypass and strategies. J Extra Corpor Technol. 2005.
9. Haemostatic function and inflammatory activation after weaning from cardiopulmonary bypass. Anki Olsson. Linköping University Medical Dissertation No 1612
10. Tommi Pätilä et al. Relation of the Sequential Organ Failure Assessment Score to Morbidity and Mortality After Cardiac Surgery. 2006 The Society of Thoracic Surgeons. Published by Elsevier Inc.
11. Michelle S Chew. Does modified ultrafiltration reduce the systemic inflammatory response to cardiac surgery with cardiopulmonary bypass? Perfusion (2004) 19, S57-S60.